Two years ago, Megan Selser was in the midst of folding her 7-week-old infant’s clothes, holding him close with his fuzzy red head nestled against her chest, when her phone suddenly rang. The voice on the other end carried a familiar tone of pain and urgency, one that Megan herself had often used in her role as an ICU nurse delivering devastating news.
It was during that phone call that Megan received the heart-wrenching news that her son Ben had been diagnosed with mucopolysaccharidosis (MPS) type 2, also known as Hunter Syndrome. This rare genetic disorder may not be immediately apparent at birth, but over time it can progressively deteriorate a child’s physical and cognitive abilities, with some children tragically passing away as young as 10 years old.
Despite the grim prognosis, there was a glimmer of hope for Ben. Thanks to a newborn screening pilot program in North Carolina, his condition was identified early on. Megan and her family were informed by doctors about promising new treatments that were undergoing clinical trials, including two gene therapies and a protein-based drug. These innovative therapies had the potential to alter the course of the disease if administered promptly.
However, the hope that Megan and her family held onto was recently dealt a significant blow. The Food and Drug Administration (FDA) recently rejected a gene therapy developed by Regenxbio for MPS, citing the need for additional data collection that could potentially delay approval by several years.
Regenxbio’s MPS drug is just one of several cell or gene therapies for rare, life-threatening diseases that the FDA has either rejected or shown signs of reversing course on in the past year. Concerns have been raised by advocates and industry executives that the agency may be shifting away from the more flexible regulatory approach that had been promised in recent years.
The rejection of promising therapies like the one developed by Regenxbio has left families like Megan’s grappling with uncertainty and disappointment. The quest for effective treatments for rare diseases remains a challenging and complex journey, with many stakeholders closely watching the regulatory landscape for signs of progress and hope.
As the search for breakthrough treatments continues, families like Megan’s remain hopeful for the day when innovative therapies will offer a lifeline to those affected by rare diseases, providing them with a chance for a brighter and healthier future.
